1. Home
  2. ICUCW vs VCEL Comparison

ICUCW vs VCEL Comparison

Compare ICUCW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • VCEL
  • Stock Information
  • Founded
  • ICUCW N/A
  • VCEL 1989
  • Country
  • ICUCW United States
  • VCEL United States
  • Employees
  • ICUCW 12
  • VCEL N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ICUCW Health Care
  • VCEL Health Care
  • Exchange
  • ICUCW Nasdaq
  • VCEL Nasdaq
  • Market Cap
  • ICUCW N/A
  • VCEL N/A
  • IPO Year
  • ICUCW 2021
  • VCEL 1997
  • Fundamental
  • Price
  • ICUCW $0.03
  • VCEL $57.09
  • Analyst Decision
  • ICUCW
  • VCEL Strong Buy
  • Analyst Count
  • ICUCW 0
  • VCEL 7
  • Target Price
  • ICUCW N/A
  • VCEL $63.29
  • AVG Volume (30 Days)
  • ICUCW N/A
  • VCEL 346.3K
  • Earning Date
  • ICUCW N/A
  • VCEL 02-27-2025
  • Dividend Yield
  • ICUCW N/A
  • VCEL N/A
  • EPS Growth
  • ICUCW N/A
  • VCEL N/A
  • EPS
  • ICUCW N/A
  • VCEL 0.07
  • Revenue
  • ICUCW N/A
  • VCEL $226,844,000.00
  • Revenue This Year
  • ICUCW N/A
  • VCEL $23.08
  • Revenue Next Year
  • ICUCW N/A
  • VCEL $21.58
  • P/E Ratio
  • ICUCW N/A
  • VCEL $794.21
  • Revenue Growth
  • ICUCW N/A
  • VCEL 22.48
  • 52 Week Low
  • ICUCW N/A
  • VCEL $39.12
  • 52 Week High
  • ICUCW N/A
  • VCEL $63.00
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • VCEL 46.07
  • Support Level
  • ICUCW N/A
  • VCEL $54.45
  • Resistance Level
  • ICUCW N/A
  • VCEL $63.00
  • Average True Range (ATR)
  • ICUCW 0.00
  • VCEL 2.17
  • MACD
  • ICUCW 0.00
  • VCEL -0.41
  • Stochastic Oscillator
  • ICUCW 0.00
  • VCEL 30.88

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: